Viridian Therapeutics, Inc.\DE (VRDN) Liabilities and Shareholders Equity (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $789.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 19.37% year-over-year to $789.0 million; the TTM figure through Mar 2026 stood at $2.8 billion (up 3.15% YoY), while the FY2025 annual figure was $899.4 million, up 21.15% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $789.0 million, down from $899.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $899.4 million in Q4 2025, with the low at $169.8 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $577.1 million (2025), against an average of $530.9 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity decreased 25.38% in 2023, then jumped 134.79% in 2024.
• Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity stood at $435.1 million in 2022, then increased by 12.72% to $490.4 million in 2023, then surged by 51.38% to $742.4 million in 2024, then advanced by 21.15% to $899.4 million in 2025, then declined by 12.27% to $789.0 million in 2026.
• Business Quant data shows VRDN's Liabilities and Shareholders Equity at $789.0 million in Q1 2026, $899.4 million in Q4 2025, and $577.1 million in Q3 2025.